Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by β-lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice

Antimicrob Agents Chemother. 2013 Nov;57(11):5423-5. doi: 10.1128/AAC.00039-13. Epub 2013 Aug 19.

Abstract

Antibiotics excreted into the intestinal tract, such as broad-spectrum cephalosporins, disrupt the indigenous microflora, affect colonization resistance (CR), and promote intestinal colonization by resistant bacteria. We tested whether oral DAV131, a charcoal-based adsorbent, would prevent colonization by a cefotaxime (CTX)-resistant Klebsiella pneumoniae strain (PUG-2) in CTX-treated mice. Mice received CTX, saline, CTX and DAV131, or saline and DAV131 for 3 days before oral challenge with 10(6) CFU of PUG-2. The fecal CTX concentrations and counts of PUG-2 were assayed. Fecal CTX disappeared when DAV131 was given concomitantly with CTX (P < 0.05), and the area under the curve of PUG-2 fecal density was significantly reduced (P < 0.01). In conclusion, reducing intestinal antibiotic exposure with DAV131 may reduce colonization by resistant strains during treatment compared to treatment with CTX only. This might open new possibilities for decreasing the impact of antibiotics on the intestinal microbiota during treatments.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Adsorption
  • Animals
  • Anti-Bacterial Agents / pharmacology*
  • Area Under Curve
  • Cefotaxime / pharmacology*
  • Charcoal / pharmacology*
  • Colony Count, Microbial
  • Drug Synergism
  • Feces / microbiology
  • Female
  • Intestines / drug effects*
  • Intestines / microbiology
  • Klebsiella Infections / drug therapy*
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / growth & development
  • Mice
  • beta-Lactam Resistance*

Substances

  • Anti-Bacterial Agents
  • Charcoal
  • Cefotaxime